[The French mesothelioma network from 1998 to 2013]

Françoise Galateau-Sallé1, A Gilg Soit Ilg2, N Le Stang3

  • 1Centre national référent cancers rares MESOPATH « mésothéliomes malins pleuraux et tumeurs péritonéales rares », CHU Caen Côte-de-Nacre, 14033 Caen cedex 9, France; Registre MESONAT, CHU Caen Côte-de-Nacre, 14033 Caen cedex 9, France.

Annales De Pathologie
|March 18, 2014
PubMed

Insights

A French mesothelioma expert network improved cancer diagnosis and patient management. This multidisciplinary approach enhanced data accuracy for research and medico-legal cases, benefiting mesothelioma patients.

Area of Science:

  • Oncology
  • Pathology
  • Epidemiology

Context:

  • Mesothelioma is a rare, aggressive cancer, primarily caused by asbestos exposure.
  • Accurate diagnosis is challenging due to heterogeneous histology, impacting early detection and treatment.
  • Rising incidence projected, necessitating improved diagnostic and research infrastructure.

Purpose:

  • To establish a multidisciplinary network for expert pathological second opinions in mesothelioma diagnosis.
  • To improve the accuracy of mesothelioma diagnosis, epidemiological data, and medico-legal assessments.
  • To create a high-quality data collection for advancing mesothelioma research.

Summary:

  • A French national network of pathologists provided expert second opinions for mesothelioma diagnosis from 1998-2013.
  • Standardized certification procedures enhanced diagnostic accuracy and consistency.
  • The network facilitated improved patient management and medico-legal case handling.

Impact:

  • Significantly improved patient management through accurate diagnosis.
  • Enhanced the quality and reliability of epidemiological data collection.
  • Facilitated a deeper understanding of mesothelioma for future research and therapeutic development.